Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX06 for SARS-CoV-2-induced ARDS
2020-002056-20Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of FX06 in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in extravascular lung water index between Day 1 and Day 7. Started Jun 2020; status: completed.
02
Drugs
FX06
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002056-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002056-20.